Malara A, Balduini A. Blood platelet manufacturing and morphology. Thrombosis Res. 2012;129:241–4.
Patel SR, Hartwig JH, Italiano JE. The biogenesis of platelets from megakaryocyte proplatelets. J Clin Make investments. 2005;115:3348–54.
Lok S, Kaushansky Okay, Holly RD, Kuijper JL, Lofton-Day CE, Oort PJ, et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet manufacturing in vivo. Nature. 1994;369:565–8.
Bruns I, Lucas D, Pinho S, Ahmed J, Lambert MP, Kunisaki Y, et al. Megakaryocytes regulate hematopoietic stem cell quiescence by CXCL4 secretion. Nat Med. 2014;20:1315–20.
Avecilla ST, Hattori Okay, Heissig B, Tejada R, Liao F, Shido Okay, et al. Chemokine-mediated interplay of hematopoietic progenitors with the bone marrow vascular area of interest is required for thrombopoiesis. Nat Med. 2004;10:64–71.
Malara A, Currao M, Gruppi C, Celesti G, Viarengo G, Buracchi C, et al. Megakaryocytes contribute to the bone marrow-matrix atmosphere by expressing fibronectin, sort IV collagen, and laminin. Stem Cells. 2014;32:926–37.
Wang J, Xie J, Wang D, Han X, Chen M, Shi G, et al. CXCR4excessive megakaryocytes regulate host-defense immunity towards bacterial pathogens. Elife. 2022;11:e78662.
Solar S, Jin C, Si J, Lei Y, Chen Okay, Cui Y, et al. Single-cell evaluation of ploidy and the transcriptome reveals practical and spatial divergency in murine megakaryopoiesis. Blood. 2021;138:1211–24.
Woods B, Chen W, Chiu S, Marinaccio C, Fu C, Gu L, et al. Activation of JAK/STAT signaling in megakaryocytes sustains myeloproliferation. Clin Most cancers Res. 2019;25:5901–12.
Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Well being Group (WHO) classification of myeloid neoplasms and acute leukemia: rationale and essential adjustments. Blood. 2009;114:937–51.
Vannucchi AM, Guglielmelli P, Tefferi A. Advances in understanding and administration of myeloproliferative neoplasms. CA Most cancers J Clin. 2009;59:171–91.
Waksal JA, Mascarenhas J. Novel therapies in myelofibrosis: past JAK inhibitors. Curr Hematol Malig Rep. 2022;17:140–54.
James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C, et al. A singular clonal JAK2 mutation resulting in constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144–8.
Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3:e270.
Nangalia J, Massie CE, Baxter EJ, Good FL, Gundem G, Wedge DC, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N. Engl J Med. 2013;369:2391–405.
Hasselbalch HC, Bjørn ME. MPNs as inflammatory illnesses: the proof, penalties, and views. Mediat Inflamm. 2015;2015:102476.
Malara A, Gruppi C, Abbonante V, Cattaneo D, De Marco L, Massa M, et al. EDA fibronectin-TLR4 axis sustains megakaryocyte growth and irritation in bone marrow fibrosis. J Exp Med. 2019;216:587–604.
Domon B, Aebersold R. Choices and concerns when choosing a quantitative proteomics technique. Nat Biotechnol. 2010;28:710–21.
Hasselbalch HC. The function of cytokines within the initiation and development of myelofibrosis. Cytokine Progress Issue Rev. 2013;24:133–45.
Malara A, Abbonante V, Zingariello M, Migliaccio A, Balduini A. Megakaryocyte contribution to bone marrow fibrosis: many arrows within the quiver. Mediterr J Hematol Infect Dis. 2018;10:e2018068.
Lambert MP, Wang Y, Bdeir KH, Nguyen Y, Kowalska MA, Poncz M. Platelet issue 4 regulates megakaryopoiesis by low-density lipoprotein receptor-related protein 1 (LRP1) on megakaryocytes. Blood. 2009;114:2290–8.
Lasagni L, Francalanci M, Annunziato F, Lazzeri E, Giannini S, Cosmi L, et al. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell progress induced by IP-10, Mig, and I-TAC, and acts as practical receptor for platelet issue 4. J Exp Med. 2003;197:1537–49.
Le HT, Golla Okay, Karimi R, Hughes MR, Lakschevitz F, Cines DB, et al. Platelet issue 4 (CXCL4/PF4) upregulates matrix metalloproteinase-2 (MMP-2) in gingival fibroblasts. Sci Rep. 2022;12:18636.
Kai Y, Yoneyama H, Koyama J, Hamada Okay, Kimura H, Matsushima Okay. Therapy with chondroitinase ABC alleviates bleomycin-induced pulmonary fibrosis. Med Mol Morphol. 2007;40:128–40.
Zou XH, Foong WC, Cao T, Bay BH, Ouyang HW, Yip GW. Chondroitin sulfate in palatal wound therapeutic. J Dent Res. 2004;83:880–5.
Schneider RK, Mullally A, Dugourd A, Peisker F, Hoogenboezem R, Van Strien PMH, et al. Gli1+ Mesenchymal Stromal Cells Are a Key Driver of Bone Marrow Fibrosis and an Necessary Mobile Therapeutic Goal. Cell Stem Cell. 2017;20:785–800.e8.
Ozono Y, Shide Okay, Kameda T, Kamiunten A, Tahira Y, Sekine M, et al. Neoplastic fibrocytes play an important function in bone marrow fibrosis in Jak2V617F-induced main myelofibrosis mice. Leukemia. 2021;35:454–67.
Verstovsek S, Manshouri T, Pilling D, Bueso-Ramos CE, Newberry KJ, Prijic S, et al. Position of neoplastic monocyte-derived fibrocytes in main myelofibrosis. J Exp Med. 2016;213:1723–40.
Decker M, Martinez-Morentin L, Wang G, Lee Y, Liu Q, Leslie J, et al. Leptin-receptor-expressing bone marrow stromal cells are myofibroblasts in main myelofibrosis. Nat Cell Biol. 2017;19:677–88.
Hasan S, Lacout C, Marty C, Cuingnet M, Solary E, Vainchenker W, et al. JAK2V617F expression in mice amplifies early hematopoietic cells and provides them a aggressive benefit that’s hampered by IFNα. Blood. 2013;122:1464–77.
Koschmieder S, Mughal TI, Hasselbalch HC, Barosi G, Valent P, Kiladjian JJ, et al. Myeloproliferative neoplasms and irritation: whether or not to focus on the malignant clone or the inflammatory course of or each. Leukemia. 2016;30:1018–24.
Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 ranges are independently prognostic in main myelofibrosis: a complete cytokine profiling examine. J Clin Oncol. 2011;29:1356–63.
Abbonante V, Di Buduo CA, Gruppi C, Malara A, Gianelli U, Celesti G, et al. Thrombopoietin/TGF-?1 loop regulates megakaryocyte extracellular matrix element synthesis. Stem Cells. 2016;34:1123–33.
Ceglia I, Dueck AC, Masiello F, Martelli F, He W, Federici G, et al. Preclinical rationale for TGF-β inhibition as a therapeutic goal for the remedy of myelofibrosis. Exp Hematol. 2016;44:1138–55.e4.
Chagraoui H, Komura E, Tulliez M, Giraudier S, Vainchenker W, Wendling F. Outstanding function of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood. 2002;100:3495–503.
Zingariello M, Martelli F, Ciaffoni F, Masiello F, Ghinassi B, D’Amore E, et al. Characterization of the TGF-β1 signaling abnormalities within the Gata1low mouse mannequin of myelofibrosis. Blood. 2013;121:3345–63.
Bock O, Loch G, Büsche G, von Wasielewski R, Schlué J, Kreipe H. Aberrant expression of platelet-derived progress issue (PDGF) and PDGF receptor-alpha is related to superior bone marrow fibrosis in idiopathic myelofibrosis. Haematologica. 2005;90:133–4.
Ciurea SO, Service provider D, Mahmud N, Ishii T, Zhao Y, Hu W, et al. Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood. 2007;110:986–93.
Zhan H, Ma Y, Lin CH, Kaushansky Okay. JAK2V617F-mutant megakaryocytes contribute to hematopoietic stem/progenitor cell growth in a mannequin of murine myeloproliferation. Leukemia. 2016;30:2332–41.
Shen Z, Du W, Perkins C, Fechter L, Natu V, Maecker H, et al. Platelet transcriptome identifies progressive markers and potential therapeutic targets in persistent myeloproliferative neoplasms. Cell Rep. Med. 2021;2:100425.
Jain Okay, Tyagi T, Du J, Hu X, Patell Okay, Martin KA, et al. Unfolded protein response differentially modulates the platelet phenotype. Circ Res. 2022;131:290–307.
Mbiandjeu S, Balduini A, Malara A. Megakaryocyte cytoskeletal proteins in platelet biogenesis and illnesses. Thromb Haemost. 2022;122:666–78.
Ghalloussi D, Dhenge A, Bergmeier W. New insights into cytoskeletal reworking throughout platelet manufacturing. J Thromb Haemost. 2019;17:1430–9.
Poulter NS, Thomas SG. Cytoskeletal regulation of platelet formation: coordination of F-actin and microtubules. Int J Biochem Cell Biol. 2015;66:69–74.
Chang Y, Auradé F, Larbret F, Zhang Y, Le Couedic JP, Momeux L, et al. Proplatelet formation is regulated by the Rho/ROCK pathway. Blood. 2007;109:4229–36.
Murphy-Ullrich JE. Thrombospondin 1 and its various roles as a regulator of extracellular matrix in fibrotic illness. J Histochem Cytochem. 2019;67:683–99.
Muth M, Engelhardt BM, Kröger N, Hussein Okay, Schlué J, Büsche G, et al. Thrombospondin-1 (TSP-1) in main myelofibrosis (PMF) – a megakaryocyte-derived biomarker which largely discriminates PMF from important thrombocythemia. Ann Hematol. 2011;90:33–40.
Evrard S, Bluteau O, Tulliez M, Rameau P, Gonin P, Zetterberg E, et al. Thrombospondin-1 is just not the foremost activator of TGF-β1 in thrombopoietin-induced myelofibrosis. Blood. 2011;117:246–9.
Leimkühler NB, Gleitz HFE, Ronghui L, Snoeren IAM, Fuchs SNR, Nagai JS, et al. Heterogeneous bone-marrow stromal progenitors drive myelofibrosis by way of a druggable alarmin axis. Cell Stem Cell. 2021;28:637–52.e8.
Affandi AJ, Carvalheiro T, Ottria A, de Haan JJ, Brans MAD, Brandt MM, et al. CXCL4 drives fibrosis by selling a number of key mobile and molecular processes. Cell Rep. 2022;38:110189.
Buka RJ, Montague SJ, Moran LA, Martin EM, Slater A, Watson SP, et al. PF4 prompts the c-Mpl-Jak2 pathway in platelets. Blood. 2024;143:64–9.
Gleitz HFE, Dugourd AJF, Leimkühler NB, Snoeren IAM, Fuchs SNR, Menzel S, et al. Elevated CXCL4 expression in hematopoietic cells hyperlinks irritation and development of bone marrow fibrosis in MPN. Blood. 2020;136:2051–64.
Martinaud C, Desterke C, Konopacki J, Pieri L, Torossian F, Golub R, et al. Osteogenic potential of mesenchymal stromal cells contributes to main myelofibrosis. Most cancers Res. 2015;75:4753–65.
Korf-Klingebiel M, Reboll MR, Grote Okay, Schleiner H, Wang Y, Wu X, et al. Heparan sulfate-editing extracellular sulfatases improve VEGF bioavailability for ischemic coronary heart restore. Circ Res. 2019;125:787–801.
Warford JR, Lamport AC, Clements DR, Malone A, Kennedy BE, Kim Y, et al. Surfen, a proteoglycan binding agent, reduces irritation however inhibits remyelination in murine fashions of A number of Sclerosis. Acta Neuropathol Commun. 2018;6:4.
Thompson S, Martínez-Burgo B, Sepuru KM, Rajarathnam Okay, Kirby JA, Sheerin NS, et al. Regulation of chemokine perform: the roles of GAG-binding and post-translational nitration. Int J Mol Sci. 2017;18:1692.
Leoni P, Rupoli S, Lai G, Brunelli MA, Belmonte MM, Pugnaloni A, et al. Platelet abnormalities in idiopathic myelofibrosis: practical, biochemical and immunomorphological correlations. Haematologica. 1994;79:29–39.
Małecki R, Gacka M, Kuliszkiewicz-Janus M, Jakobsche-Policht U, Kwiatkowski J, Adamiec R, et al. Altered plasma fibrin clot properties in important thrombocythemia. Platelets. 2016;27:110–6.
Meier-Abt F, Wolski WE, Tan G, Kummer S, Amon S, Manz MG, et al. Decreased CXCL4/PF4 expression as a driver of elevated human hematopoietic stem and progenitor cell proliferation in polycythemia vera. Blood Most cancers J. 2021;11:31.
Katoh O, Kimura A, Kuramoto A. Platelet-derived progress issue is decreased in sufferers with myeloproliferative issues. Am J Hematol. 1988;27:276–80.
Starlinger P, Moll HP, Assinger A, Nemeth C, Hoetzenecker Okay, Gruenberger B, et al. Thrombospondin-1: a novel marker to establish in vitro platelet activation when monitoring in vivo processes. J Thromb Haemost. 2010;8:1809–19.
